Background: Few studies report the incidence of metastatic patterns in colorectal cancer. Furthermore, little is known about dynamic aspects of these metastases during the course of disease. Methods: This retrospective cohort study involved 385 patients who received anti-tumor treatment at our institution (Department of Medical Oncology, University Hospital Grosshadern, Ludwig-Maximilians-University Munich, Germany) for metastatic colorectal adenocarcinoma between 2007 and 2014. We reviewed all available imaging results of these patients to document the presence and detailed localization of metastases. Results: Most of the evaluated patients were initially diagnosed with metastases in the liver (70%), followed by the lungs (24%), distant lymph nodes (16%), and peritoneum (15%), besides rare anatomical sites (<5%). Colon and rectal cancer as well as synchronous and metachronous metastases differed with regard to the pattern of individual metastatic sites. The median time to first progressive disease (PD) with new metastases was 12.6 months. The time intervals between first and second as well as second and third PD with new metastases were comparable with 10.5 and 10.8 months, respectively. At initial diagnosis, the mean number of metastatic sites was 1.4 and increased to 2.6 at the third PD with new metastases. For patients with initially one metastatic site, the mean number increased to 2.2. Conclusion: The present analysis provides detailed information on the pattern and evolution of colorectal cancer metastases over time. Thus, it may establish the basis for prospective future research in this field.

Keywords:
Metastatic colorectal cancer, Localization, Incidence, Development of metastases, Metachronous metastases, Synchronous metastases
1.
Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (eds): Krebs in Deutschland 2011/2012, ed 10. Berlin, 2015.
2.
van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, de Wilt JH: Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis 2015;32:457-465.
3.
van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, Verhoef C: Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 2012;14:56-61.
4.
Elferink MA, de Jong KP, Klaase JM, Siemerink EJ, de Wilt JH: Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands. Int J Colorectal Dis 2015;30:205-212.
5.
Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J: Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006;93:1115-1122.
6.
Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006;244:254-259.
7.
Ghiringhelli F, Hennequin A, Drouillard A, Lepage C, Faivre J, Bouvier AM: Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study. Dig Liver Dis 2014;46:854-858.
8.
Lipsyc M, Yaeger R: Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol 2015;6:645-649.
9.
Merkel S, Weber K, Croner RS, Golcher H, Gohl J, Agaimy A, Semrau S, Siebler J, Wein A, Hohenberger W, Wittekind C: Distant metastases in colorectal carcinoma: a proposal for a new M1 subclassification. Eur J Surg Oncol 2016;42:1337-1342.
10.
Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-317.
11.
Sorbye H, Kohne CH, Sargent DJ, Glimelius B: Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 2007;18:1666-1672.
12.
Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM: Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 2010;59:1383-1388.
13.
Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS: Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer 2014;120:1482-1490.
14.
Hong TS, Clark JW, Haigis KM: Cancers of the colon and rectum: identical or fraternal twins? Cancer Discov 2012;2:117-121.
15.
Urosevic J, Garcia-Albeniz X, Planet E, Real S, Cespedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S, Pavlovic M, Mangues R, Dolado I, Barriga FM, Nadal C, Kemeny N, Batlle E, Nebreda AR, Gomis RR: Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat Cell Biol 2014;16:685-694.
16.
Guo Q, Zhao Y, Chen J, Hu J, Wang S, Zhang D, Sun Y: BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. Oncol Lett 2014;8:869-875.
17.
Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-4632.
18.
Kim MJ, Lee HS, Kim JH, Kim YJ, Kwon JH, Lee JO, Bang SM, Park KU, Kim DW, Kang SB, Kim JS, Lee JS, Lee KW: Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 2012;12:347.
19.
Gayyed MF, Abd El-Maqsoud NM, El-Hameed El-Heeny AA, Mohammed MF: c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases. J Gastrointest Oncol 2015;6:618-627.
20.
Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014;25:1995-2001.
21.
Slesser AA, Georgiou P, Brown G, Mudan S, Goldin R, Tekkis P: The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clin Exp Metastasis 2013;30:457-470.
22.
Kohne CH, Poston G, Folprecht G, Ciardiello F, Ronga P, Beier F, Van Cutsem E: FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: a retrospective subgroup analysis of the CRYSTAL study. Eur J Surg Oncol 2016;42:1540-1547.
23.
Kennecke H, Yu J, Gill S, Cheung WY, Blanke CD, Speers C, Woods R: Effect of M1a and M1b category in metastatic colorectal cancer. Oncologist 2014;19:720-726.
24.
Choi HJ, Ju W, Myung SK, Kim Y: Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci 2010;101:1471-1479.
25.
Gonzalez-Moreno S, Gonzalez-Bayon L, Ortega-Perez G, Gonzalez-Hernando C: Imaging of peritoneal carcinomatosis. Cancer J 2009;15:184-189.
© 2017 S. Karger GmbH, Freiburg
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.